Jyong Biotech (MENS)
Develops botanical drug candidates for urinary-system diseases.
$2.24
Pre-market0.00 (0.00%)
At close$2.24(−1.32%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | — | — | — | — | 1 | — | 2 | |
| Research & development | — | — | — | 0 | 0 | 0 | 0 | 0 |
| — | 0 | 0 | — | — | 0 | — | 1 | |
| General & administrative | 0 | — | — | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | — | — | — | — | −1 | — | −2 |
| 0 | — | — | 0 | 0 | 0 | 0 | −2 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 0 | 0 | 0 | — | — | −1 | — | −3 |
| Net income from continuing operations | 0 | 0 | 0 | — | — | −1 | — | −3 |
| Net income | 0 | 0 | 0 | — | — | −1 | — | −3 |
| EPS, basic | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −$0.02 | −$0.02 | −$0.05 |
| EPS, diluted | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −$0.02 | −$0.02 | −$0.05 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 72 | 0 | 74 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 72 | 0 | 74 |
| EBITDA | 0 | — | — | — | — | −1 | — | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | — | — | — | — | −1 | — | −2 |